Arrowhead Pharma Stock Price, News & Analysis

Arrowhead Pharmaceuticals has formed a joint venture, Visirna Therapeutics, with Vivo Capital to develop four RNAi-based therapies for cardiometabolic diseases in Greater China. Vivo Capital's initial investment amounts to $60 million. Arrowhead retains majority ownership and is eligible for potential royalties on product sales. Visirna will manage local clinical development and has begun recruiting its leadership team in Shanghai to ensure effective engagement with the Chinese biopharma landscape.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on May 10, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 second quarter, ending March 31, 2022. Investors can access the live audio via the company's website. A replay will be available shortly after the call, lasting for 90 days. Arrowhead focuses on RNA interference therapies to combat intractable diseases, employing a range of RNA chemistries for effective gene silencing.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced on April 1, 2022, the approval of inducement grants totaling 53,000 restricted stock units for 23 new employees. These grants, approved by the Compensation Committee, fall under Rule 5635(c)(4) of the NASDAQ Listing Rules and are not part of the company's stockholder-approved equity incentive plans. The restricted stock units will vest annually over a period of four years, incentivizing employee retention and aligning interests with long-term company performance.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will participate in significant upcoming events: the 31st APASL Conference from March 30 to April 3, 2022, presenting research on RNA Interference for Hepatitis B; the AACR Annual Meeting from April 8 to 13, 2022, discussing HIF2a targeting; and the Oligo22 Conference from April 25 to 27, 2022, featuring presentations on JNJ-3989 and ARO-HIF2. These events highlight Arrowhead's commitment to advancing RNAi-based therapeutics targeting diseases such as Hepatitis B and cancer.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has filed for clearance to initiate a Phase 1/2a clinical trial for its investigational RNA interference therapy, ARO-MUC5AC, aimed at treating asthma and muco-obstructive pulmonary diseases. The trial will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in 42 healthy volunteers and 16 asthma patients. Additionally, a Pulmonary R&D Day is scheduled for May 26, 2022, in New York, where further details about the therapy and the company’s pipeline will be shared.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an application to initiate a Phase 1/2a clinical trial for ARO-RAGE, an investigational RNA interference therapeutic aimed at treating asthma and inflammatory pulmonary diseases. This innovative treatment targets the receptor for advanced glycation end products (RAGE). The application has been sent to both a local Ethics Committee and New Zealand's Medicines Authority. The upcoming study will assess the safety, tolerability, and pharmacokinetics of ARO-RAGE in 64 healthy volunteers and 16 asthma patients.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has successfully completed enrollment for the Phase 2b ARCHES-2 clinical study of its investigational RNAi therapeutic, ARO-ANG3, targeting mixed dyslipidemia with over 180 participants. The trial aims to assess the safety and efficacy of various doses, with topline data expected in the first half of 2023. The study evaluates the ability of ARO-ANG3 to inhibit ANGPTL3, which plays a role in lipid metabolism. Results will inform future late-stage clinical trials.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated dosing in the AROC3-1001 Phase 1/2 clinical study for ARO-C3, an RNA interference therapeutic targeting complement component 3 (C3). This study evaluates ARO-C3's safety and effectiveness in treating complement-mediated diseases such as IgA nephropathy and paroxysmal nocturnal hemoglobinuria. The trial includes up to 62 subjects and aims to assess various dosing regimens. With promising preclinical data, Arrowhead expects ARO-C3 to address significant unmet medical needs in this therapeutic area.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced positive interim results from the Phase 1b AROHIF21001 trial for ARO-HIF2, targeting clear cell renal cell carcinoma (ccRCC). The study showed a significant reduction in HIF2α expression, with 9 out of 14 patients demonstrating decreased protein levels. In terms of safety, ARO-HIF2 was well-tolerated, with 12% of patients reporting anemia and hypoxia. The data, presented at the 2022 ASCO GU symposium, highlighted a 39% disease control rate across all cohorts, underscoring the potential of ARO-HIF2 as a therapeutic option in ccRCC.